Arch Gen Psychiatry. 1977 Mar;34(3):297-301.

Temporal effects of drug and placebo in delaying relapse in schizophrenic outpatients.

Abstract

The potential for unwanted side effects, particularly tardive dyskinesia, following long-term after care maintenance with antipsychotic medication has led to serious questioning of its continued use for schizophrenic patients. Does the risk of relapse decline with the passage of time? If so, is the advantage of drug therapy sustained and large enough to justify continued treatment beyond one or two years? More appropriate methods for analyzing the after care experience of 374 schizophrenic patients treated with drug or placebo reveals that while the risk of relapse does decline substantially, it remains twice as high for placebo-treated patients than drug-treated patients even after two years of treatment. The prophylactic effect of maintenance chemotherapy appears to be one to two times larger than generally estimated by the less precise "cumulative percentage" method.

PMID:: 190970; [PubMed - indexed for MEDLINE]

Publication Types, MeSH Terms, Substances

Publication Types

MeSH Terms

Substances

LinkOut - more resources

Full Text Sources

Other Literature Sources

Labome Researcher Resource - ExactAntigen/Labome

Medical

Schizophrenia - MedlinePlus Health Information

Molecular Biology Databases

Supplemental Content

Icon for Silverchair Information Systems

Save items

Related citations in PubMed

[Follow-up treatment of schizophrenic psychoses: advantages and disadvantages of long-term medication]. [Arzneimittelforschung. 1978]
[Follow-up treatment of schizophrenic psychoses: advantages and disadvantages of long-term medication].
Steuber H, Kind J, Lohrengel S, Müller P. Arzneimittelforschung. 1978; 28(9):1492-3.
Review [Cost-effectiveness analysis of schizophrenic patient care settings: impact of an atypical antipsychotic under long-acting injection formulation]. [Encephale. 2005]
Review [Cost-effectiveness analysis of schizophrenic patient care settings: impact of an atypical antipsychotic under long-acting injection formulation].
Llorca PM, Miadi-Fargier H, Lançon C, Jasso Mosqueda G, Casadebaig F, Philippe A, Guillon P, Mehnert A, Omnès LF, Chicoye A, et al. Encephale. 2005 Mar-Apr; 31(2):235-46.
Fluphenazine decanoate, fluphenazine hydrochloride given orally, and placebo in remitted schizophrenics. I. Relapse rates after one year. [Arch Gen Psychiatry. 1977]
Fluphenazine decanoate, fluphenazine hydrochloride given orally, and placebo in remitted schizophrenics. I. Relapse rates after one year.
Rifkin A, Quitkin F, Rabiner CJ, Klein DF. Arch Gen Psychiatry. 1977 Jan; 34(1):43-7.
Drug and sociotherapy in the aftercare of schizophrenic patients. One-year relapse rates. [Arch Gen Psychiatry. 1973]
Drug and sociotherapy in the aftercare of schizophrenic patients. One-year relapse rates.
Hogarty GE, Goldberg SC. Arch Gen Psychiatry. 1973 Jan; 28(1):54-64.
Review Mitoxantrone: a review of its use in multiple sclerosis. [CNS Drugs. 2004]
Review Mitoxantrone: a review of its use in multiple sclerosis.
Scott LJ, Figgitt DP. CNS Drugs. 2004; 18(6):379-96.

See reviews... See all...

Cited by 3 PubMed Central articles

Tardive dyskinesia. [Br Med J (Clin Res Ed). 1981]
Tardive dyskinesia.
Abrahamson D. Br Med J (Clin Res Ed). 1981 Jun 20; 282(6281):2057.
Review Pharmacologic features and effects of neuroleptics. [Can Med Assoc J. 1981]
Review Pharmacologic features and effects of neuroleptics.
Seeman MV. Can Med Assoc J. 1981 Oct 15; 125(8):821-6.
Low dose maintenance medication for schizophrenia. [Br Med J (Clin Res Ed). 1986]
Low dose maintenance medication for schizophrenia.
Manchanda R, Hirsch SR. Br Med J (Clin Res Ed). 1986 Aug 30; 293(6546):515-6.

Related information

Related Citations
Calculated set of PubMed citations closely related to the selected article(s) retrieved using a word weight algorithm. Related articles are displayed in ranked order from most to least relevant, with the “linked from” citation displayed first.
Compound (MeSH Keyword)
PubChem chemical compound records that are classified under the same Medical Subject Headings (MeSH) controlled vocabulary as the current articles.
Substance (MeSH Keyword)
PubChem chemical substance (submitted) records that are classified under the same Medical Subject Headings (MeSH) controlled vocabulary as the current articles.
Cited in PMC
Full-text articles in the PubMed Central Database that cite the current articles.

Recent activity

Clear Turn Off Turn On

Temporal effects of drug and placebo in delaying relapse in schizophrenic outpat...
Temporal effects of drug and placebo in delaying relapse in schizophrenic outpatients.
Arch Gen Psychiatry. 1977 Mar ;34(3):297-301.

PubMed
Differentiation of primary central nervous system lymphoma and high-grade glioma...
Differentiation of primary central nervous system lymphoma and high-grade glioma with dynamic susceptibility contrast-enhanced perfusion magnetic resonance imaging.
Acta Radiol. 2009 Mar ;50(2):217-25.

PubMed
Rhinitis medicamentosa: what an otolaryngologist needs to know.
Rhinitis medicamentosa: what an otolaryngologist needs to know.
Eur Arch Otorhinolaryngol. 2009 May ;266(5):623-5. Epub 2008 Dec 19 .

PubMed
Endoscopic transcolonic catheter-free pelvic abscess drainage.
Endoscopic transcolonic catheter-free pelvic abscess drainage.
Can J Gastroenterol. 2008 Dec ;22(12):983-6.

PubMed
The Genetic Basis of HIV-1 Resistance to Reverse Transcriptase and Protease Inhi...
The Genetic Basis of HIV-1 Resistance to Reverse Transcriptase and Protease Inhibitors.
AIDS Rev. 2000;2(4):211-228.

PubMed

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

PubMed

Result Filters

Display Settings:

Send to: